MIF was predicted to interact with CD8+ T cells through the CD74 receptor and MDK with NK cells through the SORL1 receptor, with interactions with tumor cells demonstrating the highest predicted probability (Supplementary Fig. 1l). Here, CD8A is linked to neoplasm.